Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 10/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | FADS1 | O60427 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17354952 | 0.80 | AURKB (0.46) | MAPK10MAPK8KDM1AKDM4EAURKA | |
| SCHEMBL17354955 | 0.80 | AURKB (0.46) | MAPK10MAPK8KDM1AKDM4EAURKA | |
| SCHEMBL8304928 | 0.78 | ADRA2A (0.48) | MAPK10MAPK8ADRA2ATRPA1ACHE | |
| SCHEMBL10831286 | 0.73 | KAT2B (0.54) | MAPK10MAPK8ACHE | |
| SCHEMBL11147779 | 0.73 | KAT2B (0.54) | MAPK10MAPK8ACHE | |
| Hydrochloric Acid SCHEMBL10831715 | 0.72 | KAT2B (0.53) | MAPK10MAPK8ACHEKDM4E | |
| SCHEMBL10831339 | 0.72 | HRH3 (0.53) | MAPK10MAPK8ACHE | |
| SCHEMBL10831519 | 0.71 | HRH3 (0.55) | MAPK10MAPK8ACHE | |
| SCHEMBL10831606 | 0.71 | HRH3 (0.55) | MAPK10MAPK8ACHE | |
| SCHEMBL7172053 | 0.71 | TRPA1 (0.54) | MAPK10ADRA2ATRPA1FADS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-6815456-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-09 | — | — | US | disclosed |
| EP-1385842-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2002085892-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | MAPK10 3544/4885MAPK8 2966/4885ADRA2A 164/4885 |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | MAPK10 3537/4885MAPK8 2938/4885ADRA2A 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.